KMT2C and breast cancer: We expect a 1:1 mutant‐to‐wildtype allele ratio in the TCGA ER+ breast cancer sample set to present as a 35:65 mutant‐to‐wildtype allele ratio for a few reasons: TCGA ER+ breast cancer samples have approximately 75% tumor purity,21 and copy number data from the TCGA demonstrate that no amplifications or deletions coincide with MLL3 mutations for these samples (Figure S1D).